Ruppert, Amy S. http://orcid.org/0000-0001-9612-6473
Booth, Allison M.
Ding, Wei http://orcid.org/0000-0001-9811-4601
Bartlett, Nancy L.
Brander, Danielle M.
Coutre, Steven
Brown, Jennifer R. http://orcid.org/0000-0003-2040-4961
Nattam, Sreenivasa
Larson, Richard A. http://orcid.org/0000-0001-9168-3203
Erba, Harry
Litzow, Mark http://orcid.org/0000-0002-9816-6302
Owen, Carolyn
Kuzma, Charles S.
Abramson, Jeremy S.
Little, Richard F. http://orcid.org/0000-0002-4091-1699
Smith, Scott E. http://orcid.org/0000-0003-3107-3221
Stone, Richard M.
Byrd, John C.
Mandrekar, Sumithra J.
Woyach, Jennifer A. http://orcid.org/0000-0002-3403-9144
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA192928)
Article History
Received: 26 January 2021
Revised: 25 June 2021
Accepted: 30 June 2021
First Online: 17 July 2021
Competing interests
: The authors would like to disclose conflicts of interest. ASR has acted as a consultant or advisor to Telios Pharma. WD has received clinical research support from Merck. NLB has acted as a consultant or advisor to Seattle Genetics, and has received clinical research support from ADC Therapeutics, Autolus, Bristol-Myers Squibb, Celgene, Forty Seven, Genentech, Immune Design, Janssen, Kite Pharma, Merck, Millennium, Pharmacyclics, and Seattle Genetics. DMB has received honoraria from Genentech, Abbvie, Teva, TG Therapeutics, has acted as a consultant or advisor to Genentech, Abbvie, Novartis Pharma SAS, Pharmacyclics, Teva, TG Therapeutics, has had travel and accommodation expenses paid for by Abbvie, Teva, and TG Therapeutics, and has declared other relationships with Novartis Pharma SAS. SC has stock and other ownership interests in Abbvie/Pharmacyclics, has received honoraria from Janssen Oncology and Pharmacyclics, has acted as a consultant or advisor to Abbie, Adpative Biotechnologies, Astellas Pharma, AstraZeneca, BeiGene, Celgene, Genentech/Roche, Gilead Sciences, Janssen Oncology, Novartis, and Pharmacyclics, has received clinical research support from Abbvie, Acerta Pharma/AstraZeneca, Celgene, Janssen Oncology, Pharmacyclics, and Takeda, provided expert testimony for Genentech, and has had travel and accommodation expenses paid for by Abbvie, BeiGene, Celgene, Genentech, Janssen Oncology, and Pharmacyclics. JRB has received honoraria from Abbvie and Janssen, has acted as a consultant or advisor to Astellas Pharma, AstraZeneca, Celgene, Gilead Sciences, Infinity Pharmaceuticals, Abbvie, Janssen, Pharmacyclics, Redx Pharma, Roche/Genentech, and Sun Pharma and has received clinical research support from Gilead Sciences. RAL has acted as a consultant or advisor to Novartis, Amgen, Ariad/Takeda, Astellas, Celgene/BMS, CVS/Caremark, Epizyme, and MorphoSys, and has received clinical research support from Novartis, Astellas, Celgene, Cellectis, Daiichi Sankyo, Forty Seven, Rafael Pharmaceuticals, and royalties from UpToDate. HE has acted as a consultant or advisor to Agios, Amgen, Astellas Pharma, Celgene, Daiichi Sankyo, Glycomimetics, Immunogen, Incyte, Jazz Pharmaceuticals, Macrogenics, Novartis, Pfizer, and Seattle Genetics, was on a Speakers’ Bureau for Agios, Celgene, Incyte, Jazz Pharmaceuticals, and Novartis, has received clinical research support from Abbvie, has declared other relationships with Celgene and Glycomimetics, and has declared uncompensated relationships with Daiichi Sankyo. ML has acted as a consultant or advisor to Newlink Genetics and Sanofi, and has received clinical research support from Abbvie, Abbvie/Genentech, Actinium Pharmaceuticals, Amgen, Astellas Pharma, Pluristem Therapeutics, and Tolero Pharmaceuticals. JSA has acted as a consultant or advisor to Abbvie, Allogene, Bayer, Bristol-Myers Squibb, Celgene, EMD Serono, Genentech, Gilead Sciences, Janssen, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma, Merck, MorphoSys, Novartis, and Verastem, and has received clinical research support from AI Therapeutics, Celgene, and Seattle Genetics. RMS has received honoraria from DAVA Pharmaceuticals, Medscape, Prime Oncology, and Research to Practice, has acted as a consultant or advisor to Abbvie, Actinium Pharmaceuticals, Ageios, Amgen, argenx, Arog, Astellas Pharma, AstraZeneca, Biolinerx, Celgene, Celgene/Jazz, Cornerstone Pharmaceuticals, Daiichi Sankyo, Gemoab, Macrogenics, Novartis, Otsuka, Pfizer, Roche/Genentech, Stemline Therapeutics, Syntrix, Takeda, Trovagene, and has received clinical research support from Abbvie/Genentech, Agios, and Novartis. JCB has acted as a consultant or advisor to Acerta Pharma, Genentech, Jazz Pharmaceuticals, and Pharmacyclics, and has received clinical research support from Acerta Pharma, Genentech, Janssen, and Pharmacyclics. SJM has acted as a consultant or advisor to Pfizer and Pique and has declared other relationships with BioGene. JAW has acted as a consultant or advisor to ArQule, AstraZeneca, Janssen, and Pharmacyclics, and has received clinical research support from Abbvie, Janssen, Karyopharm Therapeutics, Loxo, MorphoSys, and Verastem. All other authors declare no competing interests.